Eyenovia: A Potential Advancement for In-Office Pupil Dilation Using Eyenovia’s Platform Technology, the Optejet®
About The Event
Join us for a virtual Key Opinion Leader (KOL) webinar with Eyenovia, featuring David Wirta, MD (Founder of the Eye Research Foundation), who will discuss the current three-drop standard of care for in-office pupil dilation (anesthetic, tropicamide, and phenylephrine), as well as the potential for Eyenovia’s leading pipeline ophthalmic spray to replace this regimen.
Eyenovia leadership will then provide a company update, focusing on its proprietary, first-in-class combination microdose formulation spray of tropicamide and phenylephrine for in-office pupil dilation. The event will highlight the potential for this product to increase patient throughput at practicing offices, improve the patient dilation experience, and to ensure more accurate drug delivery with less drug excess.
Eyenovia’s Mydcombi™ New Drug Application is under review by FDA, and the PDUFA date is May 8, 2023.
A live question and answer session will follow the formal presentations.